Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back


Michiko N. Fukuda

Sanford-Burnham-Prebys Medical Discovery Institute, USA

Biography

It is widely accepted that surfaces of the vasculature express varying tissue-specific receptors under different pathological conditions1. Oh et al. used subtractive proteomics analysis of malignant vs. normal vasculature to identify Annexin A1 (ANXA1) as a highly specific surface marker of malignant tumor vasculature 2, 3. Independently, in mouse studies we reported that IF7 peptide, IFLLWQR, which binds the ANXA1 N-terminus, functions as a tumor vasculature-targeted drug delivery vehicle after intravenous injection4-6. To enhance IF7 stability in vivo, we undertook mirror-image peptide phage display using a synthetic D-peptide representing the ANXA1 N-terminus as target. We then identified candidate L-peptide sequences, synthesized them using D-amino acids, and found that one peptide bound to the L-ANXA1 N-terminus. We designated that peptide dTIT7. When we injected mouse brain tumor

Abstract

Abstract : Use of annexin A1-binding peptides as an orally-administrable tumor vasculaturetargeting therapeutic